HEPA
Price
$0.47
Change
-$0.01 (-2.08%)
Updated
Apr 4, 04:59 PM (EDT)
Capitalization
516.56K
KRYS
Price
$170.94
Change
-$7.19 (-4.04%)
Updated
Apr 4, 04:59 PM (EDT)
Capitalization
5.13B
36 days until earnings call
Ad is loading...

HEPA vs KRYS

Header iconHEPA vs KRYS Comparison
Open Charts HEPA vs KRYSBanner chart's image
Hepion Pharmaceuticals
Price$0.47
Change-$0.01 (-2.08%)
Volume$445
Capitalization516.56K
Krystal Biotech
Price$170.94
Change-$7.19 (-4.04%)
Volume$2.68K
Capitalization5.13B
HEPA vs KRYS Comparison Chart
Loading...
HEPA
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
KRYS
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
View a ticker or compare two or three
VS
HEPA vs. KRYS commentary
Apr 07, 2025

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is HEPA is a Hold and KRYS is a Buy.

Ad is loading...
COMPARISON
Comparison
Apr 07, 2025
Stock price -- (HEPA: $0.48 vs. KRYS: $178.13)
Brand notoriety: HEPA and KRYS are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: HEPA: 95% vs. KRYS: 238%
Market capitalization -- HEPA: $516.56K vs. KRYS: $5.13B
HEPA [@Biotechnology] is valued at $516.56K. KRYS’s [@Biotechnology] market capitalization is $5.13B. The market cap for tickers in the [@Biotechnology] industry ranges from $299.64B to $0. The average market capitalization across the [@Biotechnology] industry is $2.18B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

HEPA’s FA Score shows that 0 FA rating(s) are green whileKRYS’s FA Score has 1 green FA rating(s).

  • HEPA’s FA Score: 0 green, 5 red.
  • KRYS’s FA Score: 1 green, 4 red.
According to our system of comparison, KRYS is a better buy in the long-term than HEPA.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

HEPA’s TA Score shows that 4 TA indicator(s) are bullish while KRYS’s TA Score has 3 bullish TA indicator(s).

  • HEPA’s TA Score: 4 bullish, 2 bearish.
  • KRYS’s TA Score: 3 bullish, 5 bearish.
According to our system of comparison, HEPA is a better buy in the short-term than KRYS.

Price Growth

HEPA (@Biotechnology) experienced а -20.69% price change this week, while KRYS (@Biotechnology) price change was -2.53% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was -10.75%. For the same industry, the average monthly price growth was -16.58%, and the average quarterly price growth was -18.37%.

Reported Earning Dates

HEPA is expected to report earnings on Aug 30, 2023.

KRYS is expected to report earnings on May 12, 2025.

Industries' Descriptions

@Biotechnology (-10.75% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
KRYS($5.13B) has a higher market cap than HEPA($517K). KRYS YTD gains are higher at: 13.705 vs. HEPA (-97.942). KRYS has more cash in the bank: 598M vs. HEPA (1.5M). HEPA has less debt than KRYS: HEPA (2.22M) vs KRYS (7.26M).
HEPAKRYSHEPA / KRYS
Capitalization517K5.13B0%
EBITDAN/A110M-
Gain YTD-97.94213.705-715%
P/E RatioN/A59.38-
RevenueN/A291M-
Total Cash1.5M598M0%
Total Debt2.22M7.26M31%
FUNDAMENTALS RATINGS
HEPA vs KRYS: Fundamental Ratings
HEPA
KRYS
OUTLOOK RATING
1..100
7875
VALUATION
overvalued / fair valued / undervalued
1..100
36
Fair valued
79
Overvalued
PROFIT vs RISK RATING
1..100
10019
SMR RATING
1..100
10067
PRICE GROWTH RATING
1..100
9947
P/E GROWTH RATING
1..100
100100
SEASONALITY SCORE
1..100
n/an/a

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

HEPA's Valuation (36) in the null industry is somewhat better than the same rating for KRYS (79) in the Pharmaceuticals Major industry. This means that HEPA’s stock grew somewhat faster than KRYS’s over the last 12 months.

KRYS's Profit vs Risk Rating (19) in the Pharmaceuticals Major industry is significantly better than the same rating for HEPA (100) in the null industry. This means that KRYS’s stock grew significantly faster than HEPA’s over the last 12 months.

KRYS's SMR Rating (67) in the Pharmaceuticals Major industry is somewhat better than the same rating for HEPA (100) in the null industry. This means that KRYS’s stock grew somewhat faster than HEPA’s over the last 12 months.

KRYS's Price Growth Rating (47) in the Pharmaceuticals Major industry is somewhat better than the same rating for HEPA (99) in the null industry. This means that KRYS’s stock grew somewhat faster than HEPA’s over the last 12 months.

KRYS's P/E Growth Rating (100) in the Pharmaceuticals Major industry is in the same range as HEPA (100) in the null industry. This means that KRYS’s stock grew similarly to HEPA’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
HEPAKRYS
RSI
ODDS (%)
Bullish Trend 6 days ago
82%
Bearish Trend 6 days ago
84%
Stochastic
ODDS (%)
N/A
Bullish Trend 6 days ago
85%
Momentum
ODDS (%)
N/A
Bearish Trend 6 days ago
80%
MACD
ODDS (%)
Bullish Trend 6 days ago
80%
Bearish Trend 6 days ago
80%
TrendWeek
ODDS (%)
Bearish Trend 6 days ago
90%
Bearish Trend 6 days ago
74%
TrendMonth
ODDS (%)
Bearish Trend 6 days ago
90%
Bearish Trend 6 days ago
75%
Advances
ODDS (%)
Bullish Trend 18 days ago
77%
Bullish Trend 19 days ago
76%
Declines
ODDS (%)
Bearish Trend 7 days ago
90%
Bearish Trend 6 days ago
76%
BollingerBands
ODDS (%)
Bullish Trend 6 days ago
86%
Bearish Trend 6 days ago
77%
Aroon
ODDS (%)
Bearish Trend 6 days ago
89%
Bullish Trend 6 days ago
74%
View a ticker or compare two or three
Ad is loading...
HEPA
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
KRYS
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
CRYPTO / NAMEPrice $Chg $Chg %
BTC.X83102.830000617.109400
+0.75%
Bitcoin cryptocurrency
SPY536.70-27.82
-4.93%
SPDR® S&P 500® ETF Trust
TSLA267.28-15.48
-5.47%
Tesla
GME21.10-1.59
-7.01%
GameStop Corp
AAPL203.19-20.70
-9.25%
Apple

HEPA and

Correlation & Price change

A.I.dvisor indicates that over the last year, HEPA has been loosely correlated with AVIR. These tickers have moved in lockstep 45% of the time. This A.I.-generated data suggests there is some statistical probability that if HEPA jumps, then AVIR could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To HEPA
1D Price
Change %
HEPA100%
+1.21%
AVIR - HEPA
45%
Loosely correlated
+0.69%
KRYS - HEPA
33%
Poorly correlated
-1.59%
LSTA - HEPA
27%
Poorly correlated
+1.45%
UBX - HEPA
23%
Poorly correlated
-6.60%
ZYME - HEPA
23%
Poorly correlated
-1.43%
More

KRYS and

Correlation & Price change

A.I.dvisor indicates that over the last year, KRYS has been loosely correlated with IDYA. These tickers have moved in lockstep 50% of the time. This A.I.-generated data suggests there is some statistical probability that if KRYS jumps, then IDYA could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To KRYS
1D Price
Change %
KRYS100%
-1.59%
IDYA - KRYS
50%
Loosely correlated
-4.77%
ACLX - KRYS
48%
Loosely correlated
-7.12%
CRNX - KRYS
48%
Loosely correlated
-8.03%
PRME - KRYS
45%
Loosely correlated
-10.06%
CGON - KRYS
45%
Loosely correlated
-15.74%
More